The Anonymous Widower

Is The Testing Of All Babies In Italy For Coeliac Disease And Type 1 Diabetes Having Any Effects?

I asked Google AI, the question in the title of this post and received this reply.

Italy’s law (Law 130/2023) targets children aged 1 to 17 rather than newborns. Pilot screening programs (like D1Ce Screen) show major positive effects: they successfully catch hidden cases early—finding coeliac antibodies in nearly 3% of children and type 1 diabetes markers in 0.8%—which dramatically cuts down dangerous emergency complications like severe diabetic ketoacidosis at diagnosis.

Key Findings and Effects

Early Detection: Finds silent or pre-symptomatic cases that standard symptom-based testing misses.

Reduced Complications: Lowers severe diabetic ketoacidosis rates by up to 50% when type 1 diabetes is caught early.

High Prevalence Insights: Pilot data show coeliac markers reach nearly 2.8–2.9% in children, higher than previous global estimates.

Healthcare Feasibility: Proves that capillary blood collection through primary care pediatricians is organized and practical on a national scale.

The testing appears to be successful in Italy.

August 2, 2026 - Posted by AnonW | Artificial Intelligence, Health | Coeliac Screening, Coeliac/Gluten-Free, Diabetes, Diabetes Screening, Google AI, Italy, Testing Of Babies For Coeliac Disease And Type 1 Diabetes In Italy